Chapter 2

Guillain-Barré Syndrome in the Emergency Deparment: A Critical Overview

Yalçın Gölcük[1]

Abstract

Guillain-Barré Syndrome (GBS) is a rare but potentially life-threatening condition that often presents in emergency departments (EDs) with acute, progressive muscle weakness and sensory disturbances. GBS is an autoimmune disorder where the immune system attacks peripheral nerves, typically following an infection such as a respiratory or gastrointestinal illness. Early recognition and prompt management are crucial for optimizing patient outcomes.

In the emergency setting, GBS should be suspected in patients presenting with rapidly progressing weakness, especially after a recent infection. The hallmark of GBS is ascending paralysis, starting in the lower limbs and potentially progressing to respiratory failure, which may require mechanical ventilation. The diagnosis is primarily clinical but is confirmed through neurophysiological studies, such as nerve conduction tests, and cerebrospinal fluid analysis, which typically shows an elevated protein level with a normal white blood cell count (albuminocytologic dissociation).

Early intervention, including the use of immunotherapy (intravenous immunoglobulin or plasmapheresis), can significantly reduce morbidity and mortality. Emergency physicians (EPs) must monitor vital signs closely, as respiratory failure and autonomic instability can occur rapidly. Additionally, supportive care, including pain management, physical therapy, and prevention of complications, is essential.

The role of EPs in managing GBS extends beyond initial stabilization. They must ensure timely referral to specialized care centers for continued management, as recovery can be prolonged and requires multidisciplinary follow-up. Understanding the critical aspects of GBS presentation and management in the ED is vital to improving patient outcomes in this potentially devastating condition.

1 Doç. Dr., Muğla Sıtkı Koçman Üniversitesi, Tıp Fakültesi, Acil Tıp Anabilim Dalı, Muğla/Türkiye, dryalcingolcuk@gmail.com, ORCID ID: 0000-0002-8530-8607

https://doi.org/10.58830/ozgur.pub692.c2927

Section 1: Introduction

Guillain-Barré syndrome (GBS) is a rare, life-threatening neurological disorder characterized by acute muscle weakness, areflexia, and often sensory and autonomic disturbances (1-3). Triggered by immune responses to infections, vaccinations, or surgeries, GBS affects the peripheral nervous system and can rapidly progress to respiratory failure and severe autonomic instability, posing significant challenges in Emergency Departments (EDs) (4,5). The pathogenesis of GBS involves an autoimmune attack on peripheral nerves, leading to demyelination or axonal damage, often following infections such as Campylobacter jejuni, cytomegalovirus, and Epstein-Barr virüs (6-8). Symptoms typically begin with symmetric limb weakness and respiratory difficulties, developing days to weeks after an inciting event, requiring prompt recognition, especially in EDs (9,10). With an incidence of 1-2 cases per 100,000 annually, GBS is more common in males and older adults (11-15). Emergency physicians (EPs) play a crucial role in early detection, as rapid progression can lead to critical complications (5,16) Timely diagnosis and treatments like intravenous immunoglobulin (IVIG) or plasma exchange can significantly improve outcomes, making EPs essential in managing this rare but critical condition (17,18).

Section 2: Pathophysiology

Understanding GBS pathophysiology is essential for EPs, guiding diagnosis and urgent treatment. GBS, an autoimmune disorder, affects the peripheral nervous system by mistakenly targeting peripheral nerves, leading to demyelination or axonal damage. This causes acute, progressive motor weakness, with varying sensory and autonomic dysfunction. Although the exact mechanism is unclear, GBS often follows an infection or immune stimulus, likely due to cross-reactivity between microbial antigens and nerve tissue—a process called molecular mimicry (19,20).

GBS pathophysiology centers on immune dysregulation affecting the peripheral nervous system, often triggered by infections such as *Campylobacter jejuni*, cytomegalovirus, or Epstein-Barr virüs (21-23). These pathogens share epitopes with peripheral nerve components, leading to an autoimmune response through molecular mimicry. In demyelinating GBS, myelin sheaths are targeted, while axonal forms like AMAN and AMSAN affect axonal membranes. Both cellular and humoral responses are activated: T-cells and macrophages infiltrate nerves, causing inflammation and demyelination, while anti-ganglioside antibodies (e.g., anti-GM1, anti-GQ1b) target neuronal membranes, resulting in immune-mediated damag (24,25).

In GBS, peripheral nerve damage arises through demyelination or axonal injury. In demyelinating types like AIDP, the immune system attacks Schwann cells, disrupting myelin and impairing nerve conduction, leading to weakness, areflexia, and sensory loss. Electrophysiology often reveals slowed conduction velocities. In axonal forms, such as AMAN and AMSAN, the immune response targets axons directly, causing degeneration and often irreversible deficits due to slower axonal regrowth. Axonal forms progress rapidly, sometimes resulting in respiratory failure and poorer outcomes, requiring prompt recognition and possible ventilatory support. Electrodiagnostic subtype classification into AIDP, AMAN or AMSAN is not helpful in the early diagnosis of GBS and currently has no bearing on management and treatment (26-29).

Autonomic nervous system involvement in GBS, affecting around 70% of cases, leads to severe complications, including arrhythmias, blood pressure instability, and gastrointestinal dysmotility. The pathophysiology remains unclear but likely involves immune-mediated damage to autonomic fibers, alongside somatic nerve damage. Cardiovascular effects, such as bradycardia, tachycardia, orthostatic hypotension, and paroxysmal hypertension, significantly increase morbidity. Gastrointestinal dysmotility, including ileus, requires careful monitoring. The autonomic system's role in homeostasis complicates GBS management, necessitating continuous monitoring and intensive supportive care to manage these life-threatening autonomic disturbances effectively (30,31).

The inflammatory processes in GBS involve a cascade of immune responses, with pro-inflammatory cytokines like IL-17, IL-6, and TNF-α playing crucial roles in the immune attack on peripheral nerves. The complement system activation forms membrane attack complexes, disrupting neural integrity and worsening nerve damage. This inflammatory response not only impairs nerve function but also increases metabolic demand, contributing to the hypermetabolic state in severe GBS cases. In axonal variants, ganglioside antibodies (e.g., anti-GM1) bind to the nodes of Ranvier, activating complement and disrupting axonal conduction, driving the aggressive progression of these forms (32,33).

The pathophysiological changes in GBS manifest as ascending, symmetric motor weakness and areflexia, with weakness typically starting in the legs and advancing to the arms and facial muscles. Severe cases may involve respiratory muscles, requiring mechanical ventilation. Sensory symptoms, though milder than motor issues, often include paresthesia and numbness. Clinical progression often mirrors the underlying pathophysiology, making

early recognition of respiratory and autonomic complications vital. Without timely intervention, these can lead to respiratory failure, arrhythmias, and high morbidity or mortality, underscoring the need for vigilance by EPs for early signs and necessary support.

Genetic and environmental factors may influence GBS development and severity. While no specific mutations are definitively linked to GBS, polymorphisms in immune-regulating genes related to T-cell activation and cytokine production are under investigation (34). Environmental triggers, such as infections or vaccinations, play a role in initiating the immune response that leads to GBS (35,36). The pathophysiology involves immune-mediated nerve damage, with varying degrees of demyelination, axonal injury, and autonomic dysfunction. For EPs, understanding these mechanisms is essential, as rapid disease progression and severe complications necessitate prompt recognition and intervention to improve patient outcomes.

Section 3: Clinical Manifestations

GBS is an acute, rapidly progressive, immune-mediated polyradiculoneuropathy, presenting a significant challenge for EPs due to its wide-ranging clinical spectrum and potential for severe, life-threatening complications. Prompt recognition and intervention in the ED are paramount to preventing irreversible morbidity, such as respiratory failure and autonomic instability. The clinical manifestations of GBS can be classified into three primary categories: motor symptoms, sensory disturbances, and autonomic dysfunction, all of which demand urgent attention in the acute care setting (37-40).

3.1. Motor Symptoms

Motor involvement is the most prominent and defining feature of GBS patients.

Progressive Muscle Weakness: The hallmark of GBS is symmetrical, ascending muscle weakness, beginning distally in the lower limbs and gradually spreading proximally. The weakness often progresses over hours to days, ascending to involve the upper limbs, facial muscles, and respiratory muscles. In the ED, it is crucial to assess the rate of progression, as patients may deteriorate rapidly. In severe cases, patients may experience quadriplegia or facial diplegia, necessitating close neurological monitoring.

Areflexia: The absence or marked reduction of deep tendon reflexes is a key diagnostic feature, present in most GBS cases. Reflexes typically

diminish early in the disease course and can provide an important diagnostic clue in the ED when coupled with progressive weakness.

Respiratory Failure: Weakness of the diaphragm and intercostal muscles can lead to respiratory insufficiency, with up to 30% of GBS patients requiring mechanical ventilation. In the ED, early recognition of impending respiratory failure is critical. Signs of respiratory compromise, such as a vital capacity <20 mL/kg or a negative inspiratory force <30 cm H_2O, should prompt immediate intervention, including possible intubation and ICU transfer. Respiratory monitoring is a cornerstone of ED management, as the progression to respiratory failure can be rapid and unpredictable.

3.2. Sensory Disturbances

Although motor symptoms dominate the clinical picture, sensory disturbances are also frequently observed in GBS patients:

Paresthesias: Mild sensory symptoms, such as tingling, numbness, or "pins and needles," often precede motor weakness and are typically more pronounced in the extremities (hands and feet). These symptoms are important early indicators but are rarely disabling.

Hypoesthesia and Sensory Loss: As the disease progresses, patients may experience diminished sensation, particularly in the distal extremities. Although less prominent than motor symptoms, sensory deficits can exacerbate functional impairment by contributing to unsteady gait or falls, particularly in older adults. EPs should conduct a thorough sensory exam to document the extent of involvement.

Pain: While not always emphasized, neuropathic pain affects up to two-thirds of patients with GBS. This pain is often described as deep, aching, or burning and may complicate management. In the ED, controlling pain with appropriate analgesia (e.g., gabapentinoids or opioids) is important for patient comfort, though this may not be a priority in the initial resuscitative phase.

3.3. Autonomic Dysfunction

Autonomic nervous system involvement is a serious and often life-threatening component of GBS, warranting meticulous monitoring in the EDs:

Cardiovascular Instability: Dysautonomia, present in up to 65% of GBS patients, can manifest as labile blood pressure (e.g., alternating hypotension and hypertension), cardiac arrhythmias (tachycardia, bradycardia, or

heart block), and orthostatic hypotension. These autonomic disturbances can cause sudden, dramatic fluctuations in vital signs, increasing the risk of syncope, cardiac arrest, or stroke. Continuous cardiac monitoring and prompt intervention are essential, especially in patients presenting with bradyarrhythmias or hypertensive emergencies.

Sudden Death Risk: Severe dysautonomia can result in fatal outcomes if not promptly recognized and managed in the ED. Bradycardia and asystole are the most feared complications. Therefore, EPs must maintain a high index of suspicion and have low thresholds for advanced cardiac life support interventions.

Gastrointestinal and Genitourinary Dysfunction: Autonomic involvement may also manifest as gastroparesis, leading to abdominal distention, nausea, and vomiting, or as urinary retention, increasing the risk of bladder overdistension or infection. In the ED, patients with suspected autonomic dysfunction should be monitored for signs of ileus or urinary retention, with appropriate interventions such as catheterization if necessary.

3.4. Cranial Nerve Involvement

Cranial neuropathy is seen in approximately 45-50% of GBS cases, and its presence can add complexity to the diagnosis in the EDs:

Facial Weakness (Bilateral Facial Diplegia): Bilateral facial weakness is common, affecting around half of GBS patients. This can lead to difficulties in facial expressions, speaking, or swallowing (dysphagia), increasing the risk of aspiration.

Ophthalmoplegia: In some cases, patients may present with ophthalmoplegia, including restricted eye movements and diplopia, due to involvement of the third, fourth, or sixth cranial nerves. This may mimic other neurological conditions, emphasizing the need for thorough neurological assessment in the ED.

Bulbar Palsy: Severe cases of GBS can involve the bulbar muscles, leading to dysarthria, dysphagia, and an increased risk of aspiration pneumonia. Patients presenting with bulbar symptoms should be monitored closely for airway compromise and referred for urgent swallowing evaluations.

3.5. Sensory-Motor Variant: Miller Fisher Syndrome

Miller Fisher Syndrome (MFS) is a rare variant of GBS, representing about 5% of GBS cases. It is characterized by the triad of ophthalmoplegia, ataxia, and areflexia. In the ED, MFS can be difficult to diagnose as patients

typically present with eye movement abnormalities and ataxia, rather than the typical limb weakness seen in GBS. Early recognition is crucial, as MFS can lead to severe complications such as respiratory failure or autonomic dysfunction, similar to classic GBS (41).

While the diagnosis is primarily clinical, an anti-GQ1b antibody test can confirm MFS, although it may not be available in the ED. Treatment with immunotherapy, including IVIG or plasmapheresis, can significantly improve outcomes. MFS generally has a better prognosis than classic GBS, but urgent identification and management are necessary to prevent further complications. ED physicians should be vigilant for MFS in patients with the characteristic triad and initiate prompt care to ensure better recovery and minimize risks.

Section 4: Diagnosis

Diagnosing GBS in the ED presents unique challenges due to the variable and often subtle early manifestations of the disease (24). GBS is a rapidly progressive, immune-mediated polyneuropathy that requires timely identification and intervention to prevent life-threatening complications, such as respiratory failure. The diagnosis of GBS involves a combination of clinical evaluation, laboratory tests, and neurophysiological studies. EPs must maintain a high index of suspicion, especially in patients presenting with progressive weakness, areflexia, and recent history of an antecedent infection.

The initial clinical assessment of patients suspected of having GBS is critical. The hallmark of GBS is the acute onset of symmetrical, ascending weakness, typically beginning in the lower limbs and progressing to involve the upper limbs and respiratory muscles (42,43). A thorough neurological examination is essential and should focus on identifying signs such as:

Weakness: Patients may report difficulty with walking, standing, or performing activities requiring fine motor skills. The weakness is typically flaccid and progressive, often ascending from the legs to the arms.

Areflexia: Deep tendon reflexes are diminished or absent in most patients with GBS. A complete loss of reflexes in the lower extremities is one of the most reliable early signs of the syndrome.

Sensory Disturbances: While sensory deficits are generally less pronounced than motor symptoms, patients may report tingling, numbness, or paresthesia, primarily in the extremities.

Autonomic Dysfunction: Signs of autonomic involvement, such as fluctuating blood pressure, cardiac arrhythmias, or bladder dysfunction, are seen in up to 70% of cases and may signal more severe disease progression.

Given the overlap of symptoms with other neurological conditions, a detailed history, including recent infections or vaccinations, is paramount in guiding the diagnosis.

Cerebrospinal fluid (CSF) analysis is a crucial diagnostic tool in confirming GBS. It typically shows elevated protein levels with a normal white blood cell count, a phenomenon known as albuminocytologic dissociation. This finding is strongly suggestive of GBS and often appears within the first week of symptom onset. However, in the very early stages of the disease, CSF protein levels may be normal, which means repeat testing may be necessary if clinical suspicion persists. This highlights the importance of ongoing monitoring in patients where GBS is suspected but not definitively diagnosed.

Nerve conduction studies and electromyography play a critical role in confirming the diagnosis of GBS. These tests demonstrate evidence of demyelination or axonal damage, depending on the subtype of GBS. Demyelinating features include slowed conduction velocities, prolonged latencies, and conduction blocks, while axonal variants may show reduced amplitude of motor responses. Early electrophysiological testing is vital in differentiating GBS from other causes of acute flaccid paralysis, such as transverse myelitis or metabolic disorders.

Although imaging studies are not routinely required for the diagnosis of GBS, magnetic resonance imaging (MRI) can be useful in excluding other conditions such as spinal cord compression or transverse myelitis in cases of diagnostic uncertainty. In some patients, MRI may show enhancement of the spinal nerve roots or cauda equina, which supports a diagnosis of GBS, particularly in patients with atypical presentations.

For a detailed review of various imaging presentations of GBS, please refer to the article on Radiopaedia.org under the title *Guillain-Barré Syndrome* (44).

Routine laboratory tests, including complete blood count, metabolic panel, and inflammatory markers, are essential to rule out alternative diagnoses that may present with similar symptoms, such as infectious or metabolic disorders. Antiganglioside antibody testing can also aid in identifying specific subtypes of GBS, particularly in patients with the Miller Fisher variant, where anti-GQ1b antibodies are commonly present.

Several diagnostic criteria have been established to aid clinicians in diagnosing GBS, the most widely used being those set forth by the National Institute of Neurological Disorders and Stroke (42,45). Key diagnostic features include:

***Progressive weakness in more than one limb*:** This is a defining characteristic of GBS, with weakness typically developing over days to weeks.

Areflexia: The absence or significant reduction of deep tendon reflexes is a critical clinical sign.

Symmetry: The weakness is usually symmetrical and predominantly affects the distal muscles before advancing proximally.

Antecedent illness: Many patients report a preceding viral or bacterial infection, most commonly gastrointestinal or respiratory in nature.

These criteria, when combined with supportive findings from CSF analysis and electrophysiological studies, allow for a timely and accurate diagnosis of GBS. Early identification of GBS is crucial for improving outcomes, as delays can lead to respiratory decline or autonomic instability. EPs should recognize early signs, such as progressive weakness and recent infections. Prompt treatment with IVIG or plasmapheresis reduces morbidity and mortality, emphasizing the importance of early intervention.

Section 5: Management Strategies

The management of GBS requires a prompt, multidisciplinary approach to prevent severe complications such as respiratory failure, autonomic instability, and permanent motor deficits. The primary goals are to stabilize the patient, mitigate the autoimmune-mediated damage, and initiate appropriate therapies to promote recovery. In the acute setting, early recognition and intervention are paramount, with supportive care, immunomodulatory treatment, and long-term monitoring forming the pillars of management. In the acute phase of GBS, immediate intervention is critical, with a focus on respiratory support, immunomodulatory therapy, and prevention of complications related to autonomic dysfunction.

Respiratory failure is a leading cause of mortality in GBS. Continuous monitoring of respiratory function is mandatory, particularly through serial assessments of forced vital capacity (FVC) and negative inspiratory force (NIF). Intubation and mechanical ventilation should be considered when the FVC drops below 20 mL/kg or the NIF falls under 30 cm H_2O. Non-invasive ventilation may be used temporarily, but invasive mechanical support should not be delayed when deterioration is suspected. Early

consultation with critical care teams is essential for patients showing signs of respiratory distress.

Plasma exchange is an established first-line treatment for GBS, aimed at reducing circulating autoantibodies and immune complexes that contribute to peripheral nerve demyelination. The typical protocol involves 5 to 6 exchanges of 40–50 mL/kg plasma per session, performed over 10–14 days, with treatment duration adjusted based on clinical severity and progression. Plasma exchange should be initiated within the first two weeks of symptom onset to maximize efficacy, as studies show improved recovery times and reduced long-term disability when therapy is administered early (46).

IVIG represents an alternative first-line treatment to plasma exchange and is especially useful in settings where plasmapheresis is contraindicated or logistically challenging (47). IVIG is administered at a dose of 2 g/kg, typically over 5 consecutive days (e.g., 400 mg/kg/day), and works by modulating the immune system and neutralizing autoantibodies. Evidence suggests that IVIG is most effective when initiated within 2 weeks of symptom onset and that it produces outcomes comparable to plasma exchange. IVIG is often preferred for its ease of administration, particularly in outpatient or resource-limited settings.

After the acute phase of GBS is managed, attention shifts to long-term recovery and rehabilitation. Early initiation of a multidisciplinary rehabilitation program is vital, starting with physical therapy focusing on range of motion, muscle strengthening, and mobility training. For patients on prolonged mechanical ventilation, respiratory rehabilitation is essential to prevent complications like ventilator-associated pneumonia. Intensive rehabilitation may last 6 to 12 months, depending on the severity. Additionally, patients are at risk for venous thromboembolism, requiring prophylactic anticoagulation. Prevention of pressure ulcers and muscle contractures is also critical, achieved through repositioning and ongoing physical therapy.

Autonomic dysfunction in GBS patients can cause serious complications such as arrhythmias, blood pressure instability, and gastrointestinal issues, affecting up to 30% of patients. Continuous monitoring of autonomic functions is vital, particularly in EDs and intensive care settings. Cardiac monitoring involves telemetry, with symptomatic bradycardia potentially requiring atropine (0.5 mg IV, repeat every 3–5 minutes, up to 3 mg). Severe bradycardia may necessitate temporary pacing. Blood pressure fluctuations should be managed with vasopressors or antihypertensive agents, depending on the patient's condition. Gastrointestinal issues like gastroparesis may be

treated with metoclopramide (10 mg orally or IV). Urinary retention can be managed with intermittent or indwelling catheterization.

Long-term follow-up is crucial for GBS patients to monitor recovery, detect relapses, and manage residual deficits (48). Neurological evaluations should be conducted periodically to assess motor and sensory function recovery. Nerve conduction studies and electromyography help evaluate nerve regeneration, with follow-up every 3 to 6 months during the first year. Chronic neuropathic pain, common in GBS survivors, requires management with medications such as gabapentin (300 mg daily, titrated up to 1200 mg) or amitriptyline (25 mg at bedtime, titrated to 100 mg daily). Pain management should be tailored to the patient, incorporating physical therapy and psychological support as needed.

Educating patients and families about GBS is essential for improving treatment adherence, recognizing early signs of relapse, and addressing psychosocial challenges. Patients should be taught to identify relapse symptoms, such as new muscle weakness, tingling, or autonomic dysfunction, to facilitate early intervention and prevent deterioration. The psychological burden of GBS requires supportive care, including counseling and access to support groups. Families should be involved in care and educated about long-term rehabilitation strategies, emphasizing the importance of continued physical and occupational therapy. In conclusion, comprehensive management involving immunomodulatory treatment, supportive care, and rehabilitation is key to improving outcomes and quality of life for GBS patients.

Section 6: Prognosis and Outcomes

The prognosis and outcomes of GBS are closely tied to the timing of diagnosis and treatment initiation (49). Early recognition and intervention can significantly mitigate the risk of complications and improve survival rates. The progression of GBS varies, but timely treatment is essential to address acute symptoms such as muscle weakness and respiratory failure, while also minimizing long-term sequelae. The presence of pre-existing conditions, such as diabetes or autoimmune disorders, can further influence recovery trajectories and the likelihood of relapses.

The short-term prognosis for GBS patients depends significantly on the severity of symptoms at treatment initiation (50). Early detection and prompt treatment are essential to minimize morbidity and mortality. Literature suggests that 5% to 10% of patients may face life-threatening complications, including respiratory failure and autonomic dysfunction.

Early administration of immunotherapy, such as IVIG or plasmapheresis, improves outcomes, with most patients showing improvement within two to four weeks. Those receiving care in intensive care settings have better short-term results, including reduced respiratory complications and shorter hospital stays, due to vigilant monitoring. EPs play a crucial role in the acute management of GBS, recognizing early symptoms like rapid weakness and sensory changes, and initiating treatment quickly. Their expertise ensures that patients receive timely immunotherapy and supportive care, improving prognosis and reducing the risk of severe complications.

The long-term prognosis for GBS varies, with 60% to 80% of patients achieving substantial recovery within six months to a year, though some may experience residual weakness, fatigue, or sensory disturbances (48). Recurrence rates are low (2% to 5%), but may occur, particularly following infections. The risk of developing Chronic Inflammatory Demyelinating Polyneuropathy may also be elevated. Cognitive and functional recovery are key to long-term outcomes. While many regain their pre-morbid functional status, 20% to 30% may have lasting impairments that affect their quality of life. Recovery is influenced by initial disability, recovery speed, and complications such as respiratory failure. A multidisciplinary approach, including neurologists and rehabilitation specialists, is often needed to support comprehensive recovery, promoting reintegration into daily activities and improving well-being.

Early recognition and timely treatment of GBS are critical for improving prognosis and preventing complications such as respiratory failure and autonomic instability. Delayed diagnosis can significantly worsen patient outcomes, while early intervention with therapies like IVIG or plasmapheresis has been shown to reduce morbidity and mortality. Establishing protocols for rapid identification of GBS in EDs allows healthcare providers to initiate treatment quickly, which is crucial for preventing severe progression. EPs, often the first to encounter these patients, play a key role in facilitating early diagnosis and intervention through rapid assessments.

Comorbid conditions, such as diabetes, chronic lung disease, and autoimmune disorders, can complicate the course of GBS and impact recovery (1,3) These conditions are associated with more severe disease presentations and longer recovery periods. Patients with pre-existing respiratory issues, for example, are at greater risk for respiratory failure, necessitating proactive management. A collaborative, multidisciplinary approach involving neurologists, physiatrists, and other healthcare providers

is essential to address the full range of patient needs, optimize treatment, and improve outcomes.

Section 7: Conclusion

In summary, GBS is a complex and potentially life-threatening condition characterized by rapid-onset muscle weakness and paralysis, often following an infectious illness. This syndrome poses significant challenges in diagnosis and management, necessitating a high level of clinical suspicion among healthcare providers, particularly in EDs. Early recognition and intervention remain paramount, as timely treatment can significantly improve both short-term and long-term outcomes.

The role of EPs is critical in the management of GBS. Their expertise in rapid assessment and decision-making can facilitate prompt interventions, thereby improving patient outcomes and reducing the risk of complications. The integration of multidisciplinary care involving neurologists, rehabilitation specialists, and primary care providers is essential in addressing the multifaceted needs of patients recovering from GBS. Such collaborative approaches enhance the efficacy of treatment and support the holistic recovery of affected individuals.

Pearls

1. **Early Recognition**: Prompt identification of GBS is critical for improving outcomes. EPs should maintain a high index of suspicion, particularly in patients presenting with rapid-onset weakness, sensory disturbances, or prior infections. Utilizing validated diagnostic criteria can aid in accurate identification.
2. **Timely Intervention**: Initiating treatment with IVIG or plasmapheresis within the first two weeks of symptom onset can significantly enhance recovery rates and reduce the severity of disability. Early intervention can help prevent complications such as respiratory failure and autonomic instability.
3. **Multidisciplinary Approach**: Employing a comprehensive care model that includes EPs, neurologists, physical therapists, and rehabilitation specialists is essential for optimizing recovery. This collaborative effort ensures that both neurological and functional rehabilitation needs are addressed, improving overall patient quality of life.

Pitfalls

1. **Delayed Diagnosis**: Misdiagnosis or delayed recognition of GBS can lead to severe complications, including respiratory failure and prolonged hospitalization. EPs should be cautious of attributing symptoms to less serious conditions and should consider GBS in patients with recent viral infections or unexplained neurological symptoms.
2. **Inadequate Monitoring**: Patients with GBS may require close monitoring for complications such as respiratory failure, autonomic dysfunction, and deep vein thrombosis. Failure to recognize the need for intensive monitoring, especially during the acute phase, can lead to adverse outcomes.
3. **Overlooking Long-term Care Needs**: After the initial recovery, patients may experience residual symptoms and functional limitations that require ongoing rehabilitation and support. Neglecting the importance of long-term follow-up and comprehensive care can adversely affect the patient's recovery trajectory and quality of life. Ensuring a smooth transition to rehabilitation services is essential for optimal recovery.

References

1. Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214-1228. doi:10.1016/S0140-6736(21)00517-1
2. Willison HJ, Jacobs BC, van Doorn PA. Guillain-Barré syndrome. Lancet. 2016;388(10045):717-727. doi:10.1016/S0140-6736(16)00339-1
3. Wakerley BR, Yuki N. Guillain-Barré syndrome. Expert Rev Neurother. 2015;15(8):847-849. doi:10.1586/14737175.2015.1065732
4. Langille MM. Guillain-Barre Syndrome in Children and Adolescents. Adv Pediatr. 2023;70(1):91-103. doi:10.1016/j.yapd.2023.04.001
5. Ganti L, Rastogi V. Acute Generalized Weakness. Emerg Med Clin North Am. 2016;34(4):795-809. doi:10.1016/j.emc.2016.06.006
6. Malek E, Salameh J. Guillain-Barre Syndrome. Semin Neurol. 2019;39(5):589-595. doi:10.1055/s-0039-1693005
7. Dash S, Pai AR, Kamath U, Rao P. Pathophysiology and diagnosis of Guillain-Barré syndrome - challenges and needs. Int J Neurosci. 2015;125(4):235-240. doi:10.3109/00207454.2014.913588
8. Shang P, Zhu M, Wang Y, et al. Axonal variants of Guillain-Barré syndrome: an update. J Neurol. 2021;268(7):2402-2419. doi:10.1007/s00415-020-09742-2
9. Elendu C, Osamuyi EI, Afolayan IA, et al. Clinical presentation and symptomatology of Guillain-Barré syndrome: A literature review. Medicine (Baltimore). 2024;103(30):e38890. doi:10.1097/MD.0000000000038890
10. Habib AA, Waheed W. Guillain-Barré Syndrome [published correction appears in Continuum (Minneap Minn). 2023 Dec 1;29(6):1921-1922. doi: 10.1212/CON.0000000000001397]. Continuum (Minneap Minn). 2023;29(5):1327-1356. doi:10.1212/CON.0000000000001289
11. Sejvar, J. J., Baughman, A. L., Wise, M., & Morgan, O. W. (2011). Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology, 36(2), 123–133. https://doi.org/10.1159/000324710
12. Xu L, Zhao C, Bao Y, et al. Variation in worldwide incidence of Guillain-Barré syndrome: a population-based study in urban China and existing global evidence. Front Immunol. 2024;15:1415986. Published 2024 Sep 10. doi:10.3389/fimmu.2024.1415986
13. Benamer HT, Bredan A. Guillain-Barré syndrome in Arab countries: a systematic review. J Neurol Sci. 2014;343(1-2):221-223. doi:10.1016/j.jns.2014.05.065

14. Bragazzi NL, Kolahi AA, Nejadghaderi SA, et al. Global, regional, and national burden of Guillain-Barré syndrome and its underlying causes from 1990 to 2019. J Neuroinflammation. 2021;18(1):264. Published 2021 Nov 11. doi:10.1186/s12974-021-02319-4

15. Levison LS, Thomsen RW, Markvardsen LK, Christensen DH, Sindrup SH, Andersen H. Pediatric Guillain-Barré Syndrome in a 30-Year Nationwide Cohort. Pediatr Neurol. 2020;107:57-63. doi:10.1016/j.pediatrneurol.2020.01.017

16. Madden J, Spadaro A, Koyfman A, Long B. High risk and low prevalence diseases: Guillain-Barré syndrome. Am J Emerg Med. 2024;75:90-97. doi:10.1016/j.ajem.2023.10.036

17. McGillicuddy DC, Walker O, Shapiro NI, Edlow JA. Guillain-Barré syndrome in the emergency department. Ann Emerg Med. 2006;47(4):390-393. doi:10.1016/j.annemergmed.2005.05.008

18. Korinthenberg R, Trollmann R, Felderhoff-Müser U, et al. Diagnosis and treatment of Guillain-Barré Syndrome in childhood and adolescence: An evidence- and consensus-based guideline. Eur J Paediatr Neurol. 2020;25:5-16. doi:10.1016/j.ejpn.2020.01.003

19. Li X, Zhang C. Guillain-Barré syndrome after surgery: a literature review. Front Neurol. 2024 Apr 4;15:1368706. doi: 10.3389/fneur.2024.1368706

20. van den Berg B, Walgaard C, Drenthen J, Fokke C, Jacobs BC, van Doorn PA. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol. 2014;10(8):469-482. doi:10.1038/nrneurol.2014.121

21. Finsterer J. Triggers of Guillain-Barré Syndrome: Campylobacter jejuni Predominates. Int J Mol Sci. 2022;23(22):14222. Published 2022 Nov 17. doi:10.3390/ijms232214222

22. Dourado Junior MET, Sousa BF, Costa NMCD, Jeronimo SMB. Cytomegalovirus infection in Guillain-Barré syndrome: a retrospective study in Brazil. Arq Neuropsiquiatr. 2021;79(7):607-611. doi:10.1590/0004-282X-ANP-2020-0464

23. Taheraghdam A, Pourkhanjar P, Talebi M, et al. Correlations between cytomegalovirus, Epstein-Barr virus, anti-ganglioside antibodies, electrodiagnostic findings and functional status in Guillain-Barré syndrome. Iran J Neurol. 2014;13(1):7-12.

24. van Doorn PA, Van den Bergh PYK, Hadden RDM, et al. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome. J Peripher Nerv Syst. 2023;28(4):535-563. doi:10.1111/jns.12594

25. Yuki N. Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(7):299-326. doi:10.2183/pjab.88.299

26. Bellanti R, Rinaldi S. Guillain-Barré syndrome: a comprehensive review. Eur J Neurol. 2024;31(8):e16365. doi:10.1111/ene.16365

27. Berciano J. The pathophysiological role of endoneurial inflammatory edema in early classical Guillain-Barré syndrome. Clin Neurol Neurosurg. 2024;237:108131. doi:10.1016/j.clineuro.2024.108131

28. Berciano J. Axonal pathology in early stages of Guillain-Barré syndrome. Neurologia (Engl Ed). 2022;37(6):466-479. doi:10.1016/j.nrleng.2020.08.001

29. Berciano J, Sedano MJ, Pelayo-Negro AL, et al. Proximal nerve lesions in early Guillain-Barré syndrome: implications for pathogenesis and disease classification. J Neurol. 2017;264(2):221-236. doi:10.1007/s00415-016-8204-2

30. Zaeem Z, Siddiqi ZA, Zochodne DW. Autonomic involvement in Guillain-Barré syndrome: an update. Clin Auton Res. 2019;29(3):289-299. doi:10.1007/s10286-018-0542-y

31. Chakraborty T, Kramer CL, Wijdicks EFM, Rabinstein AA. Dysautonomia in Guillain-Barré Syndrome: Prevalence, Clinical Spectrum, and Outcomes. Neurocrit Care. 2020;32(1):113-120. doi:10.1007/s12028-019-00781-w

32. Sun T, Chen X, Shi S, Liu Q, Cheng Y. Peripheral Blood and Cerebrospinal Fluid Cytokine Levels in Guillain Barré Syndrome: A Systematic Review and Meta-Analysis. Front Neurosci. 2019;13:717. Published 2019 Jul 16. doi:10.3389/fnins.2019.00717

33. Li X, Yang L, Wang G, et al. Extensive cytokine biomarker analysis in serum of Guillain-Barré syndrome patients. Sci Rep. 2023;13(1):8354. Published 2023 May 23. doi:10.1038/s41598-023-35610-w

34. Khanmohammadi S, Malekpour M, Jabbari P, Rezaei N. Genetic basis of Guillain-Barre syndrome. J Neuroimmunol. 2021;358:577651. doi:10.1016/j.jneuroim.2021.577651

35. Shao SC, Wang CH, Chang KC, Hung MJ, Chen HY, Liao SC. Guillain-Barré Syndrome Associated with COVID-19 Vaccination. Emerg Infect Dis. 2021;27(12):3175-3178. doi:10.3201/eid2712.211634

36. Israeli E, Agmon-Levin N, Blank M, Chapman J, Shoenfeld Y. Guillain-Barré syndrome--a classical autoimmune disease triggered by infection or vaccination. Clin Rev Allergy Immunol. 2012;42(2):121-130. doi:10.1007/s12016-010-8213-3

37. Sheikh KA. Guillain-Barré Syndrome. Continuum (Minneap Minn). 2020;26(5):1184-1204. doi:10.1212/CON.0000000000000929

38. Lee SU, Kim HJ, Choi JY, Choi KD, Kim JS. Expanding Clinical Spectrum of Anti-GQ1b Antibody Syndrome: A Review. JAMA Neurol. 2024;81(7):762-770. doi:10.1001/jamaneurol.2024.1123

39. Cao X, Guo J, Yang Y, Yu Z, Pan H, Zhou W. Clinical characteristics of Guillain-Barré syndrome in patients with primary Sjögren's syndrome. Sci Rep. 2024;14(1):5783. Published 2024 Mar 9. doi:10.1038/s41598-024-56365-y

40. Kong L, Wang J, Wu X, et al. Distribution characteristics of antinuclear antibodies in Guillain-Barré syndrome and its relationship with disease severity. Clin Neurol Neurosurg. 2024;244:108421. doi:10.1016/j.clineuro.2024.108421

41. Wakerley BR, Uncini A, Yuki N; GBS Classification Group; GBS Classification Group. Guillain-Barré and Miller Fisher syndromes--new diagnostic classification [published correction appears in Nat Rev Neurol. 2014 Nov;10(11):612]. Nat Rev Neurol. 2014;10(9):537-544. doi:10.1038/nrneurol.2014.138

42. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain. 2014;137(Pt 1):33-43. doi:10.1093/brain/awt285

43. van Doorn PA. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). Presse Med. 2013;42(6 Pt 2):e193-e201. doi:10.1016/j.lpm.2013.02.328

44. Sharma R. Guillain-Barré syndrome. Radiopaedia. Updated October 6, 2024. Accessed November 14, 2024. https://radiopaedia.org/articles/guillain-barre-syndrome-2

45. Leonhard SE, Mandarakas MR, Gondim FAA, et al. Diagnosis and management of Guillain-Barré syndrome in ten steps. Nat Rev Neurol. 2019;15(11):671-683. doi:10.1038/s41582-019-0250-9

46. Chevret S, Hughes RA, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2017;2(2):CD001798. Published 2017 Feb 27. doi:10.1002/14651858.CD001798.pub3

47. Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2014;2014(9):CD002063. Published 2014 Sep 19. doi:10.1002/14651858.CD002063.pub6

48. Haridy NA, Shehab MM, Khedr EM. Long-term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barré Syndrome: A double-blind, randomized clinical trial. Restor Neurol Neurosci. 2023;41(5-6):203-217. doi:10.3233/RNN-231369

49. Busl KM, Fried H, Muehlschlegel S, et al. Guidelines for Neuroprognostication in Adults with Guillain-Barré Syndrome [published correction

appears in Neurocrit Care. 2023 Jun;38(3):832. doi: 10.1007/s12028-023-01726-0] [published correction appears in Neurocrit Care. 2023 Dec;39(3):752. doi: 10.1007/s12028-023-01830-1]. Neurocrit Care. 2023;38(3):564-583. doi:10.1007/s12028-023-01707-3

50. Wen P, Wang L, Liu H, et al. Risk factors for the severity of Guillain-Barré syndrome and predictors of short-term prognosis of severe Guillain-Barré syndrome. Sci Rep. 2021;11(1):11578. Published 2021 Jun 2. doi:10.1038/s41598-021-91132-3